Spyre Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $89,423 | $188,893 |
| Marketable securities | 513,665 | 150,384 |
| Prepaid expenses and other current assets | 5,386 | 2,251 |
| Total current assets | 608,474 | 341,528 |
| Restricted cash | — | 322 |
| Other non-current assets | 10 | 9 |
| TOTAL ASSETS | $608,484 | $341,859 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $666 | $896 |
| CVR liability | 25,080 | 1,390 |
| Accrued and other current liabilities | 27,711 | 13,108 |
| Related party accounts payable | 603 | 16,584 |
| Total current liabilities | 54,060 | 31,978 |
| Non-current CVR liability | 36,620 | 41,310 |
| TOTAL LIABILITIES | 90,680 | 73,288 |
| Commitments and Contingencies (Note 8, Note 9) | ||
| Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 shares authorized, issued, and outstanding as of December 31, 2023. | — | 84,555 |
| STOCKHOLDERS’ EQUITY | ||
| Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 shares authorized as of December 31, 2024 and December 31, 2023; 346,045 and 437,037 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively. | 146,425 | 184,927 |
| Series B non-voting convertible preferred stock, $0.0001 par value; 271,625 shares authorized and 16,667 shares issued and outstanding as of December 31, 2024. | 9,395 | — |
| Preferred stock, $0.0001 par value; 8,642,034 shares and 8,763,659 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding as of December 31, 2024 and December 31, 2023. | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 60,257,023 shares and 36,057,109 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively. | 13 | 10 |
| Additional paid-in capital | 1,334,223 | 763,191 |
| Accumulated other comprehensive income | 180 | 302 |
| Accumulated deficit | (972,432) | (764,414) |
| TOTAL STOCKHOLDERS’ EQUITY | 517,804 | 184,016 |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | $608,484 | $341,859 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.